Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis

Robert Wilson, Timothy Aksamit, Stefano Aliberti, Anthony De Soyza, J. Stuart Elborn, Pieter Goeminne, Adam T. Hill, Rosario Menendez, Eva Polverino

Research output: Contribution to journalReview article

32 Citations (Scopus)

Abstract

Background An Expert Forum was held at the 2014 European Respiratory Society International Congress to address issues involved in the management of Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis (NCFB). Multiple studies have found that chronic P. aeruginosa infection is associated with more severe disease and higher morbidity and mortality. Overview Participants discussed appropriate management of P. aeruginosa infection at three stages: 1) first isolation, including eradication protocols; 2) during exacerbations; and 3) during chronic infection, including long-term antibiotic therapy to reduce the severity of symptoms and frequency of exacerbations. Topics covered included frequency of sputum cultures, antibiotic treatment at first isolation and for exacerbations, optimal use of inhaled antibiotics, indications for long-term therapy, and treatment regimens that may reduce the frequency or severity of symptoms. Electronic polling and roundtable discussions followed by expert insights were used to address these topics. Significant diversity in management practices was reported among different countries and centres, and in many cases clinical management was at variance with published guidelines. Conclusions This Expert Forum identified standardised terminology, clinician training, additional research into management strategies, and the development of new drugs as areas requiring improvement for the optimal management of P. aeruginosa in NCFB.

Original languageEnglish (US)
Pages (from-to)179-189
Number of pages11
JournalRespiratory Medicine
Volume117
DOIs
StatePublished - Aug 1 2016

Fingerprint

Bronchiectasis
Pseudomonas Infections
Pseudomonas aeruginosa
Fibrosis
Anti-Bacterial Agents
Practice Management
Case Management
Therapeutics
Sputum
Terminology
Guidelines
Morbidity
Mortality
Infection
Research
Pharmaceutical Preparations

Keywords

  • Airway inflammation
  • Antibiotics
  • Clinical management
  • Lower airway infection
  • Non-CF bronchiectasis
  • Pseudomonas aeruginosa

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine

Cite this

Wilson, R., Aksamit, T., Aliberti, S., De Soyza, A., Elborn, J. S., Goeminne, P., ... Polverino, E. (2016). Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. Respiratory Medicine, 117, 179-189. https://doi.org/10.1016/j.rmed.2016.06.007

Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. / Wilson, Robert; Aksamit, Timothy; Aliberti, Stefano; De Soyza, Anthony; Elborn, J. Stuart; Goeminne, Pieter; Hill, Adam T.; Menendez, Rosario; Polverino, Eva.

In: Respiratory Medicine, Vol. 117, 01.08.2016, p. 179-189.

Research output: Contribution to journalReview article

Wilson, R, Aksamit, T, Aliberti, S, De Soyza, A, Elborn, JS, Goeminne, P, Hill, AT, Menendez, R & Polverino, E 2016, 'Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis', Respiratory Medicine, vol. 117, pp. 179-189. https://doi.org/10.1016/j.rmed.2016.06.007
Wilson, Robert ; Aksamit, Timothy ; Aliberti, Stefano ; De Soyza, Anthony ; Elborn, J. Stuart ; Goeminne, Pieter ; Hill, Adam T. ; Menendez, Rosario ; Polverino, Eva. / Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis. In: Respiratory Medicine. 2016 ; Vol. 117. pp. 179-189.
@article{f59dec66643342e7a04004ca4f55a176,
title = "Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis",
abstract = "Background An Expert Forum was held at the 2014 European Respiratory Society International Congress to address issues involved in the management of Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis (NCFB). Multiple studies have found that chronic P. aeruginosa infection is associated with more severe disease and higher morbidity and mortality. Overview Participants discussed appropriate management of P. aeruginosa infection at three stages: 1) first isolation, including eradication protocols; 2) during exacerbations; and 3) during chronic infection, including long-term antibiotic therapy to reduce the severity of symptoms and frequency of exacerbations. Topics covered included frequency of sputum cultures, antibiotic treatment at first isolation and for exacerbations, optimal use of inhaled antibiotics, indications for long-term therapy, and treatment regimens that may reduce the frequency or severity of symptoms. Electronic polling and roundtable discussions followed by expert insights were used to address these topics. Significant diversity in management practices was reported among different countries and centres, and in many cases clinical management was at variance with published guidelines. Conclusions This Expert Forum identified standardised terminology, clinician training, additional research into management strategies, and the development of new drugs as areas requiring improvement for the optimal management of P. aeruginosa in NCFB.",
keywords = "Airway inflammation, Antibiotics, Clinical management, Lower airway infection, Non-CF bronchiectasis, Pseudomonas aeruginosa",
author = "Robert Wilson and Timothy Aksamit and Stefano Aliberti and {De Soyza}, Anthony and Elborn, {J. Stuart} and Pieter Goeminne and Hill, {Adam T.} and Rosario Menendez and Eva Polverino",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.rmed.2016.06.007",
language = "English (US)",
volume = "117",
pages = "179--189",
journal = "Respiratory Medicine",
issn = "0954-6111",
publisher = "W.B. Saunders Ltd",

}

TY - JOUR

T1 - Challenges in managing Pseudomonas aeruginosa in non-cystic fibrosis bronchiectasis

AU - Wilson, Robert

AU - Aksamit, Timothy

AU - Aliberti, Stefano

AU - De Soyza, Anthony

AU - Elborn, J. Stuart

AU - Goeminne, Pieter

AU - Hill, Adam T.

AU - Menendez, Rosario

AU - Polverino, Eva

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Background An Expert Forum was held at the 2014 European Respiratory Society International Congress to address issues involved in the management of Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis (NCFB). Multiple studies have found that chronic P. aeruginosa infection is associated with more severe disease and higher morbidity and mortality. Overview Participants discussed appropriate management of P. aeruginosa infection at three stages: 1) first isolation, including eradication protocols; 2) during exacerbations; and 3) during chronic infection, including long-term antibiotic therapy to reduce the severity of symptoms and frequency of exacerbations. Topics covered included frequency of sputum cultures, antibiotic treatment at first isolation and for exacerbations, optimal use of inhaled antibiotics, indications for long-term therapy, and treatment regimens that may reduce the frequency or severity of symptoms. Electronic polling and roundtable discussions followed by expert insights were used to address these topics. Significant diversity in management practices was reported among different countries and centres, and in many cases clinical management was at variance with published guidelines. Conclusions This Expert Forum identified standardised terminology, clinician training, additional research into management strategies, and the development of new drugs as areas requiring improvement for the optimal management of P. aeruginosa in NCFB.

AB - Background An Expert Forum was held at the 2014 European Respiratory Society International Congress to address issues involved in the management of Pseudomonas aeruginosa infection in patients with non-cystic fibrosis bronchiectasis (NCFB). Multiple studies have found that chronic P. aeruginosa infection is associated with more severe disease and higher morbidity and mortality. Overview Participants discussed appropriate management of P. aeruginosa infection at three stages: 1) first isolation, including eradication protocols; 2) during exacerbations; and 3) during chronic infection, including long-term antibiotic therapy to reduce the severity of symptoms and frequency of exacerbations. Topics covered included frequency of sputum cultures, antibiotic treatment at first isolation and for exacerbations, optimal use of inhaled antibiotics, indications for long-term therapy, and treatment regimens that may reduce the frequency or severity of symptoms. Electronic polling and roundtable discussions followed by expert insights were used to address these topics. Significant diversity in management practices was reported among different countries and centres, and in many cases clinical management was at variance with published guidelines. Conclusions This Expert Forum identified standardised terminology, clinician training, additional research into management strategies, and the development of new drugs as areas requiring improvement for the optimal management of P. aeruginosa in NCFB.

KW - Airway inflammation

KW - Antibiotics

KW - Clinical management

KW - Lower airway infection

KW - Non-CF bronchiectasis

KW - Pseudomonas aeruginosa

UR - http://www.scopus.com/inward/record.url?scp=84975780485&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975780485&partnerID=8YFLogxK

U2 - 10.1016/j.rmed.2016.06.007

DO - 10.1016/j.rmed.2016.06.007

M3 - Review article

C2 - 27492530

AN - SCOPUS:84975780485

VL - 117

SP - 179

EP - 189

JO - Respiratory Medicine

JF - Respiratory Medicine

SN - 0954-6111

ER -